Speech alterations have been reported in manifest Huntington’s disease (HD) and premanifest mutation carriers (preHD). The aim of our study was to explore these alterations in preHD and whether they can be used as biomarkers. 13 preHD mutation carriers performed reading task, sustained phonation task and syllable repetition tasks at baseline and after 21 months, as well as clinical examination and MRI. Syllable repetition capacity and self-chosen velocity of single syllable repetition differed significantly between time points. There were no changes in clinical ratings or MRI volumetry. Measurements of speech might be sensitive tools for monitoring subclinical changes in preHD.
LudlowCL, ConnorNPandBassichCJ. Speech timing in Parkinson’s and Huntington’s disease. Brain and Language1987; 32: 195–214.
2.
SkoddaS, SchlegelU, HoffmannR, et al.Impaired motor speech performance in Huntington’s disease. J Neural Transm2014; 121: 399–407.
3.
SkoddaS, GronheitW, LukasC, et al.Two different phenomena in basic motor speech performance in premanifest Huntington disease. Neurology2016; 86: 1329–1335.
4.
RoweKC, PaulsenJS, LangbehnDR, et al.Self-paced timing detects and tracks change in prodromal Huntington diseaseNeuropsychology. 2010; 24: 435–442.
VogelAP, ShirbinC, ChurchyardAJ, et al.Speech acoustic markers of early stage and prodromal Huntington’s disease: A marker of disease onset?Neuropsychologia2012; 50: 3273–3278.
7.
RuszJ, SaftC, SchlegelU, et al.Phonatory dysfunction as apreclinical symptom of Huntington disease. PloS One2014; 9: e113412.
8.
KoubaT, FrankW, TykalovaT, et al.Speech biomarkers in Huntington’s disease: A cross-sectional study in pre-symptomatic, prodromal and early manifest stages. Eur J Neurol2023; 30: 1262–1271.
BechtelN, ScahillRI, RosasHD, et al.Tapping linked to function and structure in premanifest and symptomatic Huntington disease. Neurology2010; 75: 2150–2160.
11.
TabriziSJ, LangbehnDR, LeavittBR, et al.Biological and clinical manifestations of Huntington’s disease in the longitudinal TRACK-HD study: Cross-sectional analysis of baseline data. Lancet Neurol2009; 8: 791–801.
12.
ScahillRI, ZeunP, Osborne-CrowleyK, et al.Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington’s disease Young Adult Study (HD-YAS): A cross-sectional analysis. Lancet Neurol2020; 19: 502–512.
13.
TabriziSJ, SchobelSA, GantmanEC, et al.A biological classification of Huntington’s disease: The Integrated Staging System (HD-ISS). Lancet Neurol2022; 21: 632–644.
14.
Unified Huntington’s Disease Rating Scale: Reliability and consistency. Huntington Study Group. Mov Disord1996; 11: 136–142.
15.
SaftC, AndrichJ, MeiselNM, et al.Assessment of complex movements reflects dysfunction in Huntington’s disease. J Neurol2003; 250: 1469–1474.
16.
SaftC, AndrichJ, MeiselNM, et al.Assessment of simple movements reflects impairment in Huntington’s disease. Mov Disord2006; 21: 1208–1212.
17.
PenneyJBJr, VonsattelJP, MacDonaldMEet al.CAG repeat number governs the development rate of pathology in Huntington’s disease. Ann Neurol1997; 41: 689–692.
18.
LangbehnDR, BrinkmanRR, FalushD, et al.A new model for prediction of the age of onset and penetrance for Huntington’s disease based on CAG length. Clin Genet2004; 65: 267–277.
19.
AylwardEH, SparksBF, FieldKM, et al.Onset and rate of striatal atrophy in preclinical Huntington disease. Neurology. 2004; 63: 66–72.
20.
DhamalaM, PagnoniG, WiesenfeldK, et al.Neural correlates of the complexity of rhythmic finger tapping. Neuroimage. 2003; 20: 918–926.
21.
BesteC, SaftC, AndrichJ, et al.Time processing in Huntington’sdisease: A group-control study. PloS One. 2007; 2: e1263.
